Hepatitis D Pipeline Analysis Report 2026

Report Coverage

The Hepatitis D Pipeline Analysis Report by Expert Market Research gives comprehensive insights into hepatitis D therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for hepatitis D. The hepatitis D report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The hepatitis D pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with hepatitis D treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to hepatitis D.

Read more about this report - Request a Free Sample

Hepatitis D Pipeline Outlook

Hepatitis D is a severe liver infection caused by the hepatitis delta virus (HDV), occurring only in individuals already infected with hepatitis B virus. It accelerates liver inflammation, often progressing to cirrhosis and liver failure within five years. Transmission occurs via blood, sexual contact, or perinatal routes, making hepatitis B co-infection a major risk factor.

Hepatitis D treatment aims at viral suppression and liver protection. Investigational therapies, including monoclonal antibodies and small interfering RNA (siRNA), target HDV RNA reduction and promote restoration of healthy liver function safely. In November 2024, Vir Biotechnology announced that its monthly tobevibart and elebsiran combination achieved rapid and sustained HDV RNA suppression in chronic hepatitis delta patients. By Week 60, up to 80% reached undetectable viral levels, supporting initiation of the Phase 3 ECLIPSE program.

Hepatitis D Epidemiology

According to the World Health Organization (WHO), Hepatitis D virus (HDV) affects approximately 5% of individuals with chronic hepatitis B virus (HBV) infection, accounting for an estimated 12 million people globally. Milaveh Assadi-Rad et al., 2024, classify HDV as a rare infectious disease in the United States, affecting fewer than 200,000 individuals. Kabo Baruti et al., 2023, estimate that 15–20 million people worldwide are infected with HDV, with the highest prevalence in Sub-Saharan Africa, particularly among people co-infected with HIV and HBV, leading to worse clinical outcomes. These epidemiological insights highlight the urgent need for targeted therapeutic development in the HDV pipeline.

Hepatitis D – Pipeline Therapeutic Assessment

Hepatitis D Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total hepatitis D clinical trials, holding 43%, reflecting active efficacy and safety evaluations. Phase III also holds 43%, highlighting candidates nearing regulatory approval and potential market entry. Phase I and phase IV each represent 7%, indicating early safety testing and post-marketing surveillance, respectively. These distributions suggest strong clinical momentum, which can accelerate treatment availability and drive hepatitis D market growth.

Hepatitis D Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the hepatitis D pipeline analysis include small molecules, monoclonal antibodies, gene therapies, peptides, and polymers. The hepatitis D report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for hepatitis D. Monoclonal antibody–based therapies are gaining prominence in the Hepatitis D drug pipeline to address unmet clinical needs. For instance, brelovitug (BJT-778), a fully human immunoglobulin G1 monoclonal antibody by Bluejay Therapeutics, is under Phase III evaluation. It targets hepatitis B surface antigen, aiming to suppress viral replication and normalize alanine aminotransferase levels in chronic hepatitis D patients.

Hepatitis D Clinical Trials – Key Players

The EMR report for the hepatitis D pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed hepatitis D therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in hepatitis D clinical trials:

• Vir Biotechnology, Inc.
• Ribocure Pharmaceuticals AB
• Gilead Sciences
• Bluejay Therapeutics, Inc.
• Shanghai HEP Pharmaceutical Co., Ltd.
• Eiger BioPharmaceuticals
• Hepatera Ltd.
• Assembly Biosciences
• Janssen Research & Development, LLC
• Hoffmann-La Roche

Hepatitis D – Emerging Drugs Profile

Key Questions Answered in the Hepatitis D Pipeline Insight Report

• Which companies/institutions are leading the hepatitis D drug development?
• Which company is leading the hepatitis D pipeline development activities?
• What is the current hepatitis D commercial assessment?
• What are the opportunities and challenges present in the hepatitis D pipeline landscape?
• What is the efficacy and safety profile of hepatitis D pipeline drugs?
• Which company is conducting major trials for hepatitis D drugs?
• Which companies/institutions are involved in hepatitis D collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in hepatitis D?

Reasons To Buy This Report

The Hepatitis D Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for hepatitis D. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into hepatitis D collaborations, regulatory environments, and potential growth opportunities.

Related Reports

Global Clinical Trials Market

Chronic Hepatitis Delta Virus (HDV) Infection Pipeline Analysis Report

Hepatitis D Epidemiology Forecast